Medication info
Rovatarin 5 mg (Rosuvastatin Calcium)

Rovatarin 5 mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Independent Bio Pharmaceutical Co., Ltd.
Appearance
Yellow round film-coated tablets
Packaging
30 tablets (15 tablets/PTP x 2)
Approval status
Active

MFDS item code 201905441 · Approved 2019.07.31

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams per day. 3. Elderly patients: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is required for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Children's dosage
Aged 10 years ∼ 17 years: The usual dosage range is 5 milligrams ∼ 20 milligrams once daily. (There are no clinical data on administration of doses higher than 20 milligrams in pediatric patients.) Under 10 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
Independent Bio Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease
  • risk of stroke
View approved original text

This medication is used as an adjunct to diet and exercise in patients with primary hypercholesterolemia and mixed dyslipidemia when they do not achieve sufficient control. It helps lower cholesterol levels in patients with homozygous familial hypercholesterolemia when used together with dietary adjustment or other treatments. It particularly lowers total cholesterol and LDL-cholesterol to target levels, delaying the progression of atherosclerosis. It is also used as an adjunct to diet in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia to reduce cholesterol and apo-B levels. Additionally, it is utilized as a dietary adjunct in patients with primary dysbetalipoproteinemia. Furthermore, this drug is used to reduce the risk of stroke, myocardial infarction, and arterial revascularization in middle-aged or older high-risk cardiovascular patients with elevated high-sensitivity C-reactive protein levels. This demonstrates its effectiveness in reducing the risk of cardiovascular disease.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams per day. 3. Elderly patients: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is required for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Children's dosage

Aged 10 years ∼ 17 years: The usual dosage range is 5 milligrams ∼ 20 milligrams once daily. (There are no clinical data on administration of doses higher than 20 milligrams in pediatric patients.) Under 10 years: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patients. For example, it should not be administered to those who are allergic to its components or have severely impaired liver function, muscle diseases, severe renal function impairment, are pregnant or breast-feeding women, or fertile women who do not use appropriate contraception. In addition, high-dose use of this medication is prohibited in patients at high risk for muscle-related diseases, which include moderate or severe renal function impairment, hypothyroidism, a history of genetic muscle diseases, and alcohol dependence. This medication contains lactose, so patients with lactose intolerance or related genetic disorders should avoid taking it. Liver function and muscle status should be regularly monitored during the administration of this medication, especially in patients with a history of excessive alcohol intake or liver disease. If symptoms like muscle pain, weakness, or cramps occur, immediate notification to healthcare professionals is necessary, and the use of this medication may need to be stopped if required. In situations where there is a risk of acute severe condition or renal failure deterioration, administration of this medication should be discontinued. This drug can, though rarely, cause severe muscle weakness and ocular myasthenia, so if these symptoms occur, discontinuation of the drug is crucial. Coadministration with certain other medications may increase the risk of muscle toxicity, so consultation with a healthcare professional is recommended when using concomitant medications. Regular renal function tests are recommended for patients on high doses. As drug exposure may be higher in Asian patients, dose adjustments may be needed. For pediatric and adolescent patients, limited impacts on growth and maturation have been reported, so careful observation is needed. Rarely, during treatment with this drug, abnormal reactions such as skin rashes, allergic reactions, liver function abnormalities, and increased risk of developing diabetes may occur. Women who are pregnant or planning to become pregnant must consult healthcare professionals and use appropriate contraception, and discontinue the medication immediately if pregnancy is confirmed. In case of overdose, there are no specific antidotes, and treatment should be symptom-based with monitoring of liver function and muscle enzymes. Caution is necessary while driving or operating machinery, as dizziness may occur. Rare side effects such as interstitial lung disease have been reported with long-term use of this medication, so immediate medical attention is required if symptoms like dyspnea or persistent coughing appear. It is important to consult with a professional immediately upon any adverse symptoms while taking this medication.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, oculobulbar weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug rash, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, elevated ALT, chest pain, muscle cramps, gout, erectile dysfunction, dizziness, elevated AST, joint pain, fatigue, numbness, sensory abnormalities, chest discomfort, anorexia, abdominal distension, abnormal liver function tests, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is important to maintain a storage temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Yellow round film-coated tablets

Package unit

30 tablets (15 tablets/PTP x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.